All In Biotech

Drug Trial Radar · NCT04707261

Association Between Dapagliflozin-induced Improvement and Anemia in Heart Failure Patients (ADIDAS)

A Prospective, Randomized, Double-blind, Multicenter Study on the Association Between Dapagliflozin-induced Improvement and Anemia in Heart Failure Patients (ADIDAS)

Last checked: Nov 19, 2026Latest source record: Jul 1, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingRandomized with 1,990 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

1,990

Planned (sponsor's estimate)

Start

Aug 6, 2021

Primary completion

May 5, 2025

Study completion Jan 1, 2026

Sponsor

Lead sponsor
Xiangtan Central HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Second Xiangya Hospital of Central South University; ZhuZhou Central Hospital
First posted
Jan 13, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Double (participant, care provider)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 100 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective of this study is to investigate the hemoglobin change and association between hemoglobin change and readmissions due to heart failure, and all-cause death in patients with heart failure treated with dapagliflozin or placebo.

Conditions

  • Anemia
  • Heart Failure

Interventions

  • DapagliflozinDrug

    Participants will receive dapagliflozin 10 mg once daily

  • PlaceboDrug

    Participants will receive placebo 10 mg once daily

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Composite number of hospital admissions for Heart Failure (HF) and all-cause deathTime frame: 1 year

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Xiangtan Central Hospital

    Xiangtan, Hunan, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.